The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Source: Inc.
07/10/26
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
The Berkeley gene-editing company will wind down its lymphoma and myeloma studies and explore a potential sale.
Source: Inc.